ZA933086B - Novel method of treatment of Parkinson's disease - Google Patents

Novel method of treatment of Parkinson's disease

Info

Publication number
ZA933086B
ZA933086B ZA933086A ZA933086A ZA933086B ZA 933086 B ZA933086 B ZA 933086B ZA 933086 A ZA933086 A ZA 933086A ZA 933086 A ZA933086 A ZA 933086A ZA 933086 B ZA933086 B ZA 933086B
Authority
ZA
South Africa
Prior art keywords
parkinson
disease
treatment
novel method
remacemide
Prior art date
Application number
ZA933086A
Other languages
English (en)
Inventor
Peter Johnson
Barry Ernest Watkins
Eric William Harris
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of ZA933086B publication Critical patent/ZA933086B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA933086A 1992-05-02 1993-04-30 Novel method of treatment of Parkinson's disease ZA933086B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209599A GB9209599D0 (en) 1992-05-02 1992-05-02 Novel therapy for the treatment of parkinsons disease

Publications (1)

Publication Number Publication Date
ZA933086B true ZA933086B (en) 1993-11-01

Family

ID=10714969

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA933086A ZA933086B (en) 1992-05-02 1993-04-30 Novel method of treatment of Parkinson's disease

Country Status (16)

Country Link
EP (1) EP0637956B1 (es)
JP (1) JP3542801B2 (es)
KR (1) KR950701216A (es)
AT (1) ATE181669T1 (es)
CA (1) CA2134783C (es)
DE (1) DE69325512T2 (es)
DK (1) DK0637956T3 (es)
ES (1) ES2135476T3 (es)
GB (1) GB9209599D0 (es)
GR (1) GR3031320T3 (es)
HU (1) HU211305A9 (es)
IL (1) IL105569A (es)
NZ (2) NZ299042A (es)
SG (1) SG49202A1 (es)
WO (1) WO1993021910A1 (es)
ZA (1) ZA933086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025369A (en) * 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639722B2 (en) * 1989-10-27 1993-08-05 Astra Aktiebolag Use of arylalkylamides in the treatment of neurodegenerative diseases
DE3940410A1 (de) * 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten

Also Published As

Publication number Publication date
IL105569A (en) 1997-11-20
ES2135476T3 (es) 1999-11-01
WO1993021910A1 (en) 1993-11-11
CA2134783A1 (en) 1993-11-11
KR950701216A (ko) 1995-03-23
DE69325512T2 (de) 1999-12-16
JPH07506105A (ja) 1995-07-06
IL105569A0 (en) 1993-08-18
DE69325512D1 (de) 1999-08-05
NZ299042A (en) 2000-07-28
NZ252728A (en) 1996-11-26
JP3542801B2 (ja) 2004-07-14
GR3031320T3 (en) 1999-12-31
SG49202A1 (en) 1998-05-18
GB9209599D0 (en) 1992-06-17
EP0637956A1 (en) 1995-02-15
ATE181669T1 (de) 1999-07-15
HU211305A9 (en) 1995-11-28
DK0637956T3 (da) 1999-11-22
CA2134783C (en) 2002-08-13
EP0637956B1 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
HK1003978A1 (en) Composition for the treatment of schizophrenia
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GB2288732B (en) Pharmaceutical compositions
ZA933086B (en) Novel method of treatment of Parkinson's disease
ITMI910658A0 (it) N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
HUT71838A (en) Use of biologically active ureido derivatives useful in the treatment of lentivirus-induced disease for producing pharmaceutical compositions
NZ268039A (en) Use of efaroxan in treating parkinson's disease
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2700115B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU96118559A (ru) Лекарственное средство
ITBO930460A0 (it) Procedimento per preparare forme farmaceutiche a rilascio controllato del principio attivo e le forme farmaceutiche cosi' ottenute.
IT1275987B1 (it) Composizione farmaceutica attiva nella cura di affezioni dermatologiche
ZA969968B (en) Use of 2-iminobenzothiazolines in the treatment of parkinson's disease and parkinsonian syndromes
TH18617B (th) เบนซิลเอมีนที่มีการเข้าแทนที่และการใช้เพื่อการรักษาโรคซึมเศร้า
TH29708A (th) เบนซิลเอมีนที่มีการเข้าแทนที่และการใช้เพื่อการรักษาโรคซึมเศร้า